Aurinia Pharmaceuticals (AUPH)

• Market cap: $1.23B
• 1 day: 2.01%
• 5 days: -0.54%
• 1 month: 7.79%
• 3 months: 10.80%
• 6 months: 14.13%
• Year to date: 4.10%
• 1 year: 62.46%
• 5 years: -31.46%
• 10 years: 145.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Employees: 300

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]

86% more call options, than puts

Call options by funds: $14.4M | Put options by funds: $7.71M

85% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 20

14% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 58

7% more funds holding

Funds holding: 197 [Q4 2024] → 210 (+13) [Q1 2025]

4.78% more ownership

Funds ownership: 40.37% [Q4 2024] → 45.14% (+4.78%) [Q1 2025]

4% less capital invested

Capital invested by funds: $519M [Q4 2024] → $499M (-$20.5M) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $17 86% upside
• Avg. target: $17 86% upside
• High target: $17 86% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Arthur He

86% upside $17

Buy Assumed

30 Jul 2025